Rachel Bystritsky, MD
Infectious Disease · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 6
- Since medical school
- 14 years
- Graduated 2012
Offices
6 locations · UCSF Medical Group Business Services · Regents of the University of California · University of California San Francisco
Hospitals listed: Mills-Peninsula Medical Center · UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Bystritsky’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A142468 · Current
Licensed to practise in California · since 2016 · expires 2028-02-29 · Icahn School of Medicine at Mount Sinai.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Infectious Disease
- American Board of Internal Medicine - Internal Medicine
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$60,182
Medicare paid this office $60,182 for 227 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 89 | $18,654 | $125 |
| Return visit (30+ min) | 84 | $13,204 | $82 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 45 | $6,999 | $103 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 125 | $4,630 | $15 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 29 | $3,360 | $116 |
See all 12 services
| Long return visit (40+ min) | 89 | $18,654 | $125 |
| Return visit (30+ min) | 84 | $13,204 | $82 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 45 | $6,999 | $103 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 125 | $4,630 | $15 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 29 | $3,360 | $116 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $2,609 | $153 |
| Telephone medical discussion with physician, 21-30 minutes | 17 | $1,999 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 22 | $1,900 | $68 |
| Short return visit (20+ min) | 26 | $1,704 | $57 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 23 | $975 | $28 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 27 | $844 | $31 |
| Telephone medical discussion with physician, 11-20 minutes | 11 | $469 | $39 |
Who their Medicare patients are
227 Original Medicare patients in 2024. Average age 71 · Under 65 19% · 85 and older 9% · Women 45% · Also on Medicaid 38% · Health risk score 2.48. At or below the middle of the specialty; the typical infectious disease clinician is at 3.
Conditions among them: High blood pressure 75% · Chronic kidney disease 38% · Depression 38% · Diabetes 37% · Coronary heart disease 33% · Heart failure 30% · COPD 28% · Atrial fibrillation 23% · Cancer 19% · Dementia 15% · Stroke 15%.
The office billed $380,261, Medicare allowed $78,343 and paid $60,182; for 961 services of 21 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 227 | 961 | 71 | 2.48 | $380,261 | $60,182 |
| 2023 | 174 | 466 | 71 | 2.88 | $262,885 | $43,909 |
| 2022 | 155 | 401 | 70 | 2.69 | $235,478 | $39,179 |
| 2021 | 211 | 523 | 67 | 2.93 | $298,472 | $49,504 |
| 2020 | 169 | 415 | 68 | 2.70 | $244,345 | $35,031 |
| 2019 | 171 | 357 | 68 | 3.02 | $221,022 | $33,303 |
| 2018 | 84 | 138 | 66 | 2.67 | $88,196 | $14,243 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Long return visit (40+ min) | 57 | $11,964 | $126 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 43 | $8,264 | $107 |
| Return visit (30+ min) | 46 | $5,375 | $80 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 30 | $4,694 | $156 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 24 | $2,808 | $117 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 25 | $2,784 | $71 |
| New patient visit (60+ min) | 17 | $2,758 | $162 |
| Short return visit (20+ min) | 20 | $1,541 | $59 |
| Prolonged hospital inpatient or observation care evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by th | 19 | $829 | $28 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 13 | $535 | $28 |
2022: 7 services
| Long return visit (40+ min) | 65 | $13,817 | $122 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 51 | $8,483 | $91 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 30 | $5,121 | $171 |
| Return visit (30+ min) | 26 | $2,804 | $85 |
| Telephone medical discussion with physician, 21-30 minutes | 13 | $1,931 | $88 |
| Short return visit (20+ min) | 22 | $1,252 | $52 |
| Telephone medical discussion with physician, 11-20 minutes | 14 | $1,012 | $53 |
2021: 11 services
| Long return visit (40+ min) | 60 | $11,382 | $126 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 49 | $8,145 | $92 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 45 | $8,054 | $179 |
| Return visit (30+ min) | 58 | $7,034 | $76 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 41 | $4,289 | $62 |
| Telephone medical discussion with physician, 21-30 minutes | 25 | $2,432 | $84 |
| New patient visit (60+ min) | 11 | $1,830 | $166 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,333 | $121 |
| Telephone medical discussion with physician, 11-20 minutes | 14 | $1,000 | $56 |
| Short return visit (20+ min) | 13 | $967 | $60 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 12 | $961 | $80 |
2020: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 55 | $8,997 | $90 |
| Return visit (30+ min) | 52 | $7,145 | $71 |
| Long return visit (40+ min) | 53 | $5,018 | $76 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 29 | $4,918 | $170 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 28 | $2,610 | $62 |
| Telephone medical discussion with physician, 21-30 minutes | 22 | $2,075 | $69 |
2019: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 60 | $10,497 | $92 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 40 | $7,167 | $179 |
| Long return visit (40+ min) | 22 | $4,949 | $92 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 30 | $3,746 | $121 |
| Return visit (30+ min) | 30 | $2,596 | $60 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 23 | $2,062 | $64 |
| Short return visit (20+ min) | 14 | $1,042 | $45 |
2018: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 33 | $4,632 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $4,141 | $180 |
| Long return visit (40+ min) | 16 | $2,073 | $99 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $1,100 | $65 |
| Return visit (30+ min) | 12 | $839 | $70 |
Medicaid work
$26,060 in 2024
Medicaid paid $26,060 for 304 billed services this clinician did in 2024, up to 19 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 122 | $17,665 |
| Return visit (30+ min) | 76 | $7,373 |
| Telehealth transmission, per minute, professional services bill separately | 106 | $1,022 |
| 2024 | 304 | 3 | 19 | $26,060 |
| 2023 | 90 | 3 | 16 | $2,582 |
| 2022 | 24 | 1 | 13 | $2,299 |
| 2021 | 16 | 1 | 16 | $1,119 |
| 2020 | 41 | 2 | 15 | $2,671 |
| 2019 | 29 | 1 | 15 | $1,746 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 14 | $1,537 |
| Telehealth originating site facility fee | 13 | $564 |
| Telehealth transmission, per minute, professional services bill separately | 63 | $481 |
2022
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 24 | $2,299 |
2021
| Return visit (30+ min) | 16 | $1,119 |
2020
| Long return visit (40+ min) | 28 | $1,701 |
| Return visit (30+ min) | 13 | $970 |
2019
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 29 | $1,746 |
Drugs they prescribed that Part D paid
$291,601
Pharmacies billed $291,601 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 814) in 2024. At or below the middle of the specialty; the typical infectious disease clinician is at 0%.
780 generic and 34 brand-name prescriptions · $291,601 in drug cost · 675 antibiotic prescriptions to 128 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Posaconazole | 16 | $20,857 | $1,304 |
| Piperacillin-Tazobactam | 21 | $5,996 | $286 |
| Vancomycin | 55 | $5,966 | $108 |
| Ertapenem | 23 | $5,538 | $241 |
| Cefpodoxime Proxetil | 14 | $4,630 | $331 |
See all 21 drugs
| Posaconazole | 16 | $20,857 | $1,304 |
| Piperacillin-Tazobactam | 21 | $5,996 | $286 |
| Vancomycin | 55 | $5,966 | $108 |
| Ertapenem | 23 | $5,538 | $241 |
| Cefpodoxime Proxetil | 14 | $4,630 | $331 |
| Doxycycline Hyclate | 132 | $4,605 | $35 |
| Micafungin | 13 | $3,882 | $299 |
| Meropenem | 19 | $2,770 | $146 |
| Fluconazole | 34 | $1,416 | $42 |
| Cefazolin | 15 | $998 | $67 |
| Amoxicillin | 48 | $936 | $19 |
| Amoxicillin-Clavulanate Potass | 39 | $676 | $17 |
| Minocycline | 21 | $582 | $28 |
| Ceftriaxone | 29 | $563 | $19 |
| Ciprofloxacin | 35 | $478 | $14 |
| Cefadroxil | 14 | $466 | $33 |
| Sulfamethoxazole-Trimethoprim | 54 | $464 | $9 |
| Doxycycline Monohydrate | 12 | $384 | $32 |
| Clindamycin | 13 | $358 | $28 |
| Rifampin | 11 | $299 | $27 |
| Penicillin V | 28 | $135 | $5 |
Year by year
| 2024 | 814 | 146 | 0% (0) | 4% | $291,601 |
| 2023 | 562 | 99 | 0% (0) | None | $193,063 |
| 2022 | 704 | 132 | 0% (0) | None | $295,129 |
| 2021 | 1,636 | 114 | 2% (33) | None | $940,418 |
| 2020 | 1,458 | 68 | 3% (47) | None | $1,001,949 |
| 2019 | 1,186 | 41 | 4% (50) | None | $950,937 |
| 2018 | 399 | 38 | 3% (11) | 37% | $280,275 |
| 2016 | 925 | 40 | None | 28% | $50,679 |
| 2015 | 1,127 | 73 | None | 30% | $69,896 |
| 2014 | 1,237 | 78 | 0% (0) | 27% | $79,699 |
| 2013 | 611 | 54 | None | 23% | $27,872 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 13 drugs
| Zerbaxa | 13 | $73,797 | $5,677 |
| Doxycycline Hyclate | 132 | $8,443 | $64 |
| Daptomycin | 11 | $8,199 | $745 |
| Ertapenem | 24 | $7,721 | $322 |
| Vancomycin | 40 | $5,329 | $133 |
| Ampicillin | 17 | $2,427 | $143 |
| Amoxicillin | 51 | $1,196 | $23 |
| Rifampin | 13 | $1,163 | $89 |
| Sulfamethoxazole-Trimethoprim | 35 | $790 | $23 |
| Ampicillin-Sulbactam | 15 | $747 | $50 |
| Fluconazole | 17 | $516 | $30 |
| Ceftriaxone | 22 | $404 | $18 |
| Atorvastatin | 11 | $35 | $3 |
2022: 14 drugs
| Vancomycin | 86 | $10,404 | $121 |
| Doxycycline Hyclate | 119 | $8,721 | $73 |
| Ertapenem | 15 | $4,625 | $308 |
| Ceftriaxone | 42 | $2,809 | $67 |
| Methenamine Hippurate | 17 | $1,448 | $85 |
| Minocycline | 15 | $1,147 | $76 |
| Doxycycline Monohydrate | 16 | $1,005 | $63 |
| Cefadroxil | 25 | $803 | $32 |
| Sulfamethoxazole-Trimethoprim | 40 | $798 | $20 |
| Ceftazidime | 14 | $786 | $56 |
| Amoxicillin | 26 | $715 | $28 |
| Cefazolin | 11 | $700 | $64 |
| Ciprofloxacin | 11 | $104 | $9 |
| Atorvastatin | 13 | $56 | $4 |
2021: 56 drugs
| Triumeq | 64 | $234,430 | $3,663 |
| Biktarvy | 56 | $207,755 | $3,710 |
| Symtuza | 23 | $98,291 | $4,274 |
| Genvoya | 18 | $60,191 | $3,344 |
| Tivicay | 18 | $33,508 | $1,862 |
| Prezista | 16 | $31,217 | $1,951 |
| Selzentry | 12 | $17,994 | $1,500 |
| Edurant | 12 | $15,379 | $1,282 |
| Vancomycin | 90 | $14,316 | $159 |
| Ertapenem | 25 | $11,144 | $446 |
| Rifabutin | 14 | $10,311 | $737 |
| Trulicity | 11 | $9,811 | $892 |
| Androderm | 12 | $7,808 | $651 |
| Oxycontin | 12 | $7,345 | $612 |
| Daptomycin | 12 | $6,576 | $548 |
| Stiolto Respimat | 12 | $5,596 | $466 |
| Symbicort | 12 | $4,742 | $395 |
| Doxycycline Hyclate | 65 | $3,411 | $52 |
| Testosterone | 13 | $3,203 | $246 |
| Cefpodoxime Proxetil | 12 | $2,261 | $188 |
| Pregabalin | 19 | $1,320 | $69 |
| Duloxetine | 15 | $1,318 | $88 |
| Valacyclovir | 32 | $969 | $30 |
| Sulfamethoxazole-Trimethoprim | 30 | $878 | $29 |
| Cefazolin | 17 | $761 | $45 |
| Atorvastatin | 80 | $726 | $9 |
| Fluticasone Propionate | 28 | $696 | $25 |
| Fluconazole | 14 | $693 | $49 |
| Cefadroxil | 18 | $586 | $33 |
| Fenofibrate | 12 | $558 | $46 |
| Amoxicillin-Clavulanate Potass | 15 | $472 | $31 |
| Ceftriaxone | 17 | $429 | $25 |
| Amlodipine Besylate | 46 | $383 | $8 |
| Lansoprazole | 11 | $373 | $34 |
| Rosuvastatin | 12 | $335 | $28 |
| Amlodipine Besylate-Benazepril | 16 | $313 | $20 |
| Levothyroxine | 30 | $310 | $10 |
| Bupropion Xl | 15 | $304 | $20 |
| Tamsulosin | 21 | $267 | $13 |
| Gabapentin | 20 | $256 | $13 |
| Omeprazole | 24 | $229 | $10 |
| Bisoprolol | 13 | $229 | $18 |
| Cephalexin | 13 | $227 | $17 |
| Finasteride | 18 | $213 | $12 |
| Allopurinol | 24 | $197 | $8 |
| Oxycodone | 14 | $191 | $14 |
| Metformin | 37 | $186 | $5 |
| Metoprolol | 14 | $184 | $13 |
| Lisinopril | 38 | $171 | $4 |
| Benazepril | 16 | $117 | $7 |
| Mirtazapine | 11 | $98 | $9 |
| Sertraline | 11 | $95 | $9 |
| Nortriptyline | 11 | $95 | $9 |
| Clonazepam | 12 | $79 | $7 |
| Carvedilol | 13 | $70 | $5 |
| Hydrochlorothiazide | 11 | $64 | $6 |
2020: 55 drugs
| Triumeq | 71 | $244,432 | $3,443 |
| Biktarvy | 45 | $170,603 | $3,791 |
| Genvoya | 31 | $121,429 | $3,917 |
| Symtuza | 17 | $69,269 | $4,075 |
| Prezista | 29 | $53,648 | $1,850 |
| Odefsey | 13 | $40,086 | $3,084 |
| Tivicay | 16 | $28,667 | $1,792 |
| Descovy | 14 | $27,293 | $1,949 |
| Creon | 13 | $22,525 | $1,733 |
| Selzentry | 12 | $19,608 | $1,634 |
| Edurant | 12 | $14,471 | $1,206 |
| Androderm | 22 | $11,797 | $536 |
| Rifabutin | 13 | $9,663 | $743 |
| Oxycontin | 12 | $8,169 | $681 |
| Testosterone | 29 | $6,097 | $210 |
| Stiolto Respimat | 11 | $4,843 | $440 |
| Basaglar Kwikpen U-100 | 13 | $4,395 | $338 |
| Vancomycin | 14 | $3,865 | $276 |
| Abacavir-Lamivudine | 14 | $3,356 | $240 |
| Loperamide | 12 | $2,154 | $180 |
| Ritonavir | 18 | $1,559 | $87 |
| Valacyclovir | 34 | $1,406 | $41 |
| Pregabalin | 24 | $1,294 | $54 |
| Rosuvastatin | 20 | $1,080 | $54 |
| Ethambutol | 11 | $1,019 | $93 |
| Duloxetine | 15 | $754 | $50 |
| Atorvastatin | 83 | $741 | $9 |
| Fluconazole | 13 | $735 | $57 |
| Ventolin Hfa | 12 | $706 | $59 |
| Cefazolin | 11 | $598 | $54 |
| Fenofibrate | 14 | $557 | $40 |
| Baclofen | 13 | $466 | $36 |
| Fluticasone Propionate | 17 | $406 | $24 |
| Levothyroxine | 34 | $396 | $12 |
| Morphine Sulfate Er | 12 | $373 | $31 |
| Ciprofloxacin | 14 | $344 | $25 |
| Amlodipine Besylate-Benazepril | 13 | $320 | $25 |
| Nortriptyline | 13 | $307 | $24 |
| Azithromycin | 13 | $284 | $22 |
| Niacin Er | 12 | $270 | $23 |
| Oxycodone | 23 | $256 | $11 |
| Amlodipine Besylate | 40 | $242 | $6 |
| Allopurinol | 28 | $193 | $7 |
| Omeprazole | 17 | $189 | $11 |
| Lisinopril | 34 | $186 | $5 |
| Fluoxetine | 17 | $182 | $11 |
| Metoprolol | 24 | $154 | $6 |
| Metformin | 27 | $140 | $5 |
| Tamsulosin | 17 | $118 | $7 |
| Acyclovir | 18 | $114 | $6 |
| Gabapentin | 15 | $112 | $7 |
| Mirtazapine | 12 | $107 | $9 |
| Benazepril | 18 | $84 | $5 |
| Sertraline | 13 | $75 | $6 |
| Carvedilol | 11 | $67 | $6 |
2019: 38 drugs
| Triumeq | 78 | $252,348 | $3,235 |
| Genvoya | 59 | $183,683 | $3,113 |
| Biktarvy | 49 | $160,815 | $3,282 |
| Odefsey | 17 | $49,670 | $2,922 |
| Prezista | 23 | $39,737 | $1,728 |
| Tivicay | 15 | $27,637 | $1,842 |
| Selzentry | 14 | $22,876 | $1,634 |
| Descovy | 11 | $19,220 | $1,747 |
| Edurant | 11 | $12,399 | $1,127 |
| Androderm | 19 | $8,722 | $459 |
| Testosterone | 24 | $7,847 | $327 |
| Morphine Sulfate Er | 20 | $3,663 | $183 |
| Loperamide | 13 | $1,401 | $108 |
| Valacyclovir | 36 | $1,318 | $37 |
| Atorvastatin | 64 | $932 | $15 |
| Fluconazole | 12 | $704 | $59 |
| Ventolin Hfa | 11 | $632 | $57 |
| Fluticasone Propionate | 25 | $477 | $19 |
| Rosuvastatin | 12 | $450 | $37 |
| Levothyroxine | 32 | $443 | $14 |
| Metoprolol | 20 | $413 | $21 |
| Fenofibrate | 13 | $362 | $28 |
| Pravastatin | 27 | $360 | $13 |
| Baclofen | 11 | $323 | $29 |
| Levetiracetam | 11 | $250 | $23 |
| Omeprazole | 23 | $244 | $11 |
| Acyclovir | 18 | $229 | $13 |
| Oxycodone | 20 | $203 | $10 |
| Tamsulosin | 19 | $196 | $10 |
| Gabapentin | 15 | $186 | $12 |
| Lisinopril | 20 | $133 | $7 |
| Gemfibrozil | 11 | $129 | $12 |
| Allopurinol | 16 | $128 | $8 |
| Amlodipine Besylate | 20 | $123 | $6 |
| Mirtazapine | 13 | $117 | $9 |
| Hydrocortisone | 11 | $107 | $10 |
| Benazepril | 15 | $101 | $7 |
| Metformin | 12 | $37 | $3 |
2018: 9 drugs
| Genvoya | 26 | $77,663 | $2,987 |
| Triumeq | 20 | $60,198 | $3,010 |
| Prezista | 14 | $22,087 | $1,578 |
| Abacavir-Lamivudine | 11 | $2,857 | $260 |
| Ampicillin-Sulbactam | 12 | $433 | $36 |
| Gabapentin | 13 | $265 | $20 |
| Pravastatin | 14 | $197 | $14 |
| Atorvastatin | 15 | $146 | $10 |
| Acyclovir | 14 | $142 | $10 |
2016: 29 drugs
| Spiriva | 16 | $5,324 | $333 |
| Xarelto | 14 | $4,910 | $351 |
| Januvia | 13 | $4,739 | $365 |
| Crestor | 17 | $4,183 | $246 |
| Nexium | 11 | $4,096 | $372 |
| Advair Diskus | 11 | $3,694 | $336 |
| Alcohol Pads | 18 | $945 | $53 |
| Metoprolol | 37 | $945 | $26 |
| Labetalol | 13 | $944 | $73 |
| Proair Hfa | 12 | $797 | $66 |
| Valsartan | 17 | $716 | $42 |
| Atorvastatin | 84 | $702 | $8 |
| Tamsulosin | 28 | $387 | $14 |
| Diltiazem 24hr Cd | 11 | $301 | $27 |
| Lisinopril | 60 | $173 | $3 |
| Furosemide | 26 | $172 | $7 |
| Amlodipine Besylate | 63 | $168 | $3 |
| Metformin | 41 | $152 | $4 |
| Simvastatin | 23 | $75 | $3 |
| Clonidine | 13 | $74 | $6 |
| Alendronate | 23 | $70 | $3 |
| Ramipril | 13 | $61 | $5 |
| Losartan | 23 | $59 | $3 |
| Metoprolol | 17 | $50 | $3 |
| Losartan-Hydrochlorothiazide | 13 | $43 | $3 |
| Carvedilol | 16 | $43 | $3 |
| Famotidine | 11 | $36 | $3 |
| Hydrochlorothiazide | 23 | $35 | $2 |
| Single Use Swab | 12 | $24 | $2 |
2015: 27 drugs
| Spiriva | 22 | $6,877 | $313 |
| Xarelto | 16 | $5,237 | $327 |
| Crestor | 23 | $4,868 | $212 |
| Advair Diskus | 12 | $3,841 | $320 |
| Omega-3 Acid Ethyl Esters | 12 | $2,327 | $194 |
| Valsartan | 16 | $1,540 | $96 |
| Atorvastatin | 106 | $1,006 | $9 |
| Metoprolol | 41 | $707 | $17 |
| Alcohol Pads | 14 | $379 | $27 |
| Lisinopril | 82 | $309 | $4 |
| Levothyroxine | 17 | $265 | $16 |
| Alcohol Prep Pads | 13 | $251 | $19 |
| Amlodipine Besylate | 91 | $246 | $3 |
| Unifine Pentips | 14 | $245 | $17 |
| Isosorbide Mononitrate Er | 16 | $220 | $14 |
| Nifedical Xl | 11 | $188 | $17 |
| Metformin | 40 | $154 | $4 |
| Alendronate | 25 | $148 | $6 |
| Losartan | 35 | $143 | $4 |
| Mirtazapine | 12 | $143 | $12 |
| Simvastatin | 27 | $123 | $5 |
| Quinapril | 15 | $102 | $7 |
| Carvedilol | 26 | $97 | $4 |
| Furosemide | 17 | $76 | $4 |
| Famotidine | 15 | $41 | $3 |
| Hydrochlorothiazide | 11 | $25 | $2 |
| Atenolol | 12 | $24 | $2 |
2014: 36 drugs
| Diclofenac | 12 | $11,307 | $942 |
| Acyclovir | 23 | $10,807 | $470 |
| Januvia | 22 | $7,164 | $326 |
| Spiriva | 13 | $3,816 | $294 |
| Crestor | 18 | $3,421 | $190 |
| Nexium | 12 | $2,899 | $242 |
| Atorvastatin | 88 | $2,472 | $28 |
| Omega-3 Acid Ethyl Esters | 12 | $2,394 | $200 |
| Diovan | 11 | $1,482 | $135 |
| Clopidogrel | 19 | $1,156 | $61 |
| Proair Hfa | 21 | $1,038 | $49 |
| Labetalol | 15 | $806 | $54 |
| Losartan | 34 | $609 | $18 |
| Metoprolol | 24 | $512 | $21 |
| Carvedilol | 44 | $417 | $9 |
| Levothyroxine | 28 | $375 | $13 |
| Lisinopril | 73 | $305 | $4 |
| Tamsulosin | 21 | $269 | $13 |
| Amlodipine Besylate | 59 | $261 | $4 |
| Simvastatin | 43 | $251 | $6 |
| Ramipril | 17 | $245 | $14 |
| Metformin | 37 | $237 | $6 |
| Omeprazole | 24 | $207 | $9 |
| Glipizide Xl | 12 | $195 | $16 |
| Pantoprazole | 16 | $178 | $11 |
| Quinapril | 18 | $158 | $9 |
| Fluticasone Propionate | 12 | $133 | $11 |
| Metoprolol | 32 | $129 | $4 |
| Triamcinolone Acetonide | 11 | $124 | $11 |
| Furosemide | 35 | $124 | $4 |
| Mirtazapine | 12 | $118 | $10 |
| Gabapentin | 14 | $112 | $8 |
| Alendronate | 13 | $107 | $8 |
| Famotidine | 13 | $75 | $6 |
| Hydrochlorothiazide | 18 | $55 | $3 |
| Single Use Swab | 13 | $34 | $3 |
2013: 17 drugs
| Lantus Solostar | 13 | $2,097 | $161 |
| Crestor | 11 | $1,912 | $174 |
| Atorvastatin | 36 | $1,075 | $30 |
| Lansoprazole | 13 | $755 | $58 |
| Losartan | 23 | $712 | $31 |
| Clopidogrel | 14 | $542 | $39 |
| Gabapentin | 27 | $295 | $11 |
| Glipizide Xl | 11 | $256 | $23 |
| Simvastatin | 35 | $201 | $6 |
| Carvedilol | 19 | $196 | $10 |
| Lisinopril | 34 | $128 | $4 |
| Metformin | 19 | $124 | $7 |
| Amlodipine Besylate | 23 | $116 | $5 |
| Glipizide | 28 | $84 | $3 |
| Metoprolol | 13 | $73 | $6 |
| Hydrochlorothiazide | 13 | $66 | $5 |
| Furosemide | 14 | $51 | $4 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 74.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1194081984
- Licence
- CA A142468California A142468: Current · expires 2028-02-29
- Group
- UCSF Medical Group Business Services · Regents of the University of California · University of California San Francisco
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RI0200X (207RI0200X)
- Mailing address
- 400 Parnassus Ave Fl 2, San Francisco, CA, 94143
- NPI first listed
- 2012-04-05
- NPI last updated
- 2020-04-16
- NPI record certified
- 2020-04-16
This is when the NPI record was last certified, not a medical board exam.